IN8BIO INC. DL-0001
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candid… Read more
IN8BIO INC. DL-0001 (6JH) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IN8BIO INC. DL-0001 (6JH) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IN8BIO INC. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how IN8BIO INC. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IN8BIO INC. DL-0001 (None–None)
The table below shows the annual net assets of IN8BIO INC. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IN8BIO INC. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IN8BIO INC. DL-0001 Competitors by Market Cap
The table below lists competitors of IN8BIO INC. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
noco-noco Inc. Warrant
NASDAQ:NCNCW
|
$419.71K |
|
Genting Hong Kong Limited
PINK:GTHKF
|
$419.71K |
|
Mustek Ltd
JSE:MST
|
$420.02K |
|
Starstream Entmt Inc
PINK:SSET
|
$420.03K |
|
Singapore Reinsurance Corporation Limited
STU:S49
|
$419.03K |
|
My Foodie BOX Ltd
AU:MBX
|
$418.97K |
|
Nutranomics Inc
PINK:NNRX
|
$418.94K |
|
IDT-B (IDC2.SG)
STU:IDC2
|
$418.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IN8BIO INC. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IN8BIO INC. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IN8BIO INC. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IN8BIO INC. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IN8BIO INC. DL-0001 (6JH) | €- | N/A | N/A | $419.46K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |